SRR12475158
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- MYC_TARGETS_V1+0.350
- DNA_REPAIR+0.310
- GLYCOLYSIS+0.290
- OXIDATIVE_PHOSPHORYLATION+0.290
- WNT_BETA_CATENIN_SIGNALING+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- FATTY_ACID_METABOLISM+0.250
- MTORC1_SIGNALING+0.250
- CHOLESTEROL_HOMEOSTASIS+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.310
- UV_RESPONSE_DN-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- ALLOGRAFT_REJECTION-0.240
- PROTEIN_SECRETION-0.200
- TNFA_SIGNALING_VIA_NFKB-0.180
- IL6_JAK_STAT3_SIGNALING-0.170
- INFLAMMATORY_RESPONSE-0.160
- COMPLEMENT-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a2f13560-4d23-4ef8-8c69-a5b6279d5b21 | — | — | 0.937 |
| 2 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.875 |
| 3 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.861 |
| 4 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.848 |
| 5 | TCGA-33-AAS8-01A-11R-A405-07 | — | cohortSQ2 | 0.836 |
| 6 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.832 |
| 7 | DRR168575 | — | — | 0.828 |
| 8 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.827 |
| 9 | 4EBF33F3-DA34-4866-81E5-F2D50A18D413 | — | — | 0.823 |
| 10 | TCGA-CV-5432-01A-02R-1686-07 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |